Non Segmental Vitiligo clinical trials

Explore recruiting non segmental vitiligo clinical trials.

Recruiting non segmental vitiligo studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Segmental Vitiligo trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vitiligo

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy

Germany, Spain, Bulgaria, Poland, France, Italy +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

J5D-MC-FPAD: A Phase 2a, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants with Non-Segmental Vitiligo

Poland, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

B7981040 - A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBOCONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO

Bulgaria, Spain, Germany, Italy, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

B7981041: A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSE-UP TITRATION, MULTICENTER EXTENSION STUDY INVESTIGATING THE SAFETY, EFFICACY, AND TOLERABILITY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS WITH NONSEGMENTAL VITILIGO

Poland, Italy, Bulgaria, Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo.

Poland, Italy, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Non Segmental Vitiligo trials by city

Non Segmental Vitiligo in Toronto Non Segmental Vitiligo in Vancouver Non Segmental Vitiligo in Montreal Non Segmental Vitiligo in Calgary Non Segmental Vitiligo in Edmonton Non Segmental Vitiligo in Ottawa Non Segmental Vitiligo in Winnipeg Non Segmental Vitiligo in Quebec City Non Segmental Vitiligo in Hamilton Non Segmental Vitiligo in Kitchener Non Segmental Vitiligo in London Non Segmental Vitiligo in Halifax Non Segmental Vitiligo in New York Non Segmental Vitiligo in Los Angeles Non Segmental Vitiligo in Chicago Non Segmental Vitiligo in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease